This study integrated network pharmacology, molecular docking and molecular dynamics simulations to systematically elucidate the potential mechanism of EMS in treating osteoarthritis, identifying key active compounds such as quercetin, wogonin, and rutaecarpine, and revealing their synergistic effects on core targets including TNF, IL‐6, and AKT1. The gene discussed is AKT1; the disease is osteoarthritis.